FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lois Ednie

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Physiology

Co-author Network

Publications

TOP 3
Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.
Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Peter C Appelbaum
Comparative antipneumococcal activities of sulopenem and other drugs.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lois Ednie (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.
Antimicrobial agents and chemotherapy 2010;54(5):2201-5.
2010: Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
Antimicrobial agents and chemotherapy 2010;54(5):2258-61.
2009: Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Peter C Appelbaum
Comparative antipneumococcal activities of sulopenem and other drugs.
Antimicrobial agents and chemotherapy 2009;53(6):2239-47.
2009: Lois M Ednie; Peter C Appelbaum
Antianaerobic activity of sulopenem compared to six other agents.
Antimicrobial agents and chemotherapy 2009;53(5):2163-70.
2009: Catherine Clark; Lois M Ednie; Gengrong Lin; Kathy Smith; Klaudia Kosowska-Shick; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Patrick Caspers; Bérangère Gaucher; Gürkan Mert; Stuart Shapiro; Peter C Appelbaum
Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
Antimicrobial agents and chemotherapy 2009;53(4):1353-61.
2008: Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Kathy Smith; Cynthia D Todd; Amanda Wehler; Peter C Appelbaum
Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.
Antimicrobial agents and chemotherapy 2008;52(12):4510-3.
2008: Kathy Smith; Lois M Ednie; Peter C Appelbaum; Stephen Hawser; Sergio Lociuro
Antistreptococcal activity of AR-709 compared to that of other agents.
Antimicrobial agents and chemotherapy 2008;52(6):2279-82.
2008: Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Bonifacio Dewasse; Linda Beachel; Lois M Ednie; Peter C Appelbaum
In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.
Antimicrobial agents and chemotherapy 2008;52(2):748-52.
2008: Catherine Clark; Kathy Smith; Lois M Ednie; Tatiana Bogdanovich; Bonifacio Dewasse; Pamela McGhee; Peter C Appelbaum
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 2008;52(1):77-84.
2008: Kim Credito; Lois M Ednie; Peter C Appelbaum
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
Antimicrobial agents and chemotherapy 2008;52(1):365-73.
2007: Catherine L Clark; Klaudia Kosowska-Shick; Lois M Ednie; Peter C Appelbaum
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Antimicrobial agents and chemotherapy 2007;51(11):4196-201.
2007: Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois M Ednie; Laura M Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
Antimicrobial agents and chemotherapy 2007;51(9):3445-8.
2007: Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
Diagnostic microbiology and infectious disease 2007;58(1):133-6.
2006: Klaudia Kosowska-Shick; Kathy Smith; Tatiana Bogdanovich; Lois M Ednie; Ronald Jones; Peter C Appelbaum
Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.
Antimicrobial agents and chemotherapy 2006;50(12):4191-4.
2006: Tatiana Bogdanovich; Catherine Clark; Lois M Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Antimicrobial agents and chemotherapy 2006;50(6):2050-7.
2005: Gengrong Lin; Kathy Smith; Lois M Ednie; Peter C Appelbaum
Antipneumococcal activity of dalbavancin compared to other agents.
Antimicrobial agents and chemotherapy 2005;49(12):5182-4.
2005: Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Antimicrobial agents and chemotherapy 2005;49(10):4210-9.
2005: Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Antimicrobial agents and chemotherapy 2005;49(8):3325-33.
2005: Gengrong Lin; Kim Credito; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
Antimicrobial agents and chemotherapy 2005;49(2):770-2.
2004: Bülent Bozdogan; Lois M Ednie; Kim Credito; Klaudia Kosowska; Peter C Appelbaum
Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center.
Antimicrobial agents and chemotherapy 2004;48(12):4762-5.
2004: Vlatka Matic; Klaudia Kosowska; Bülent Bozdogan; Linda M Kelly; Kathy Smith; Lois M Ednie; Gengrong Lin; Kim Credito; Catherine L Clark; Pamela McGhee; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Antimicrobial agents and chemotherapy 2004;48(11):4103-12.
2004: Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Antimicrobial agents and chemotherapy 2004;48(10):4033-6.
2004: Lois M Ednie; Glenn A Pankuch; Peter C Appelbaum
Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Antimicrobial agents and chemotherapy 2004;48(10):4027-32.
2004: George A Syrogiannopoulos; Bülent Bozdogan; Ioanna N Grivea; Lois M Ednie; Dimitra I Kritikou; George D Katopodis; Nicholas G Beratis; Peter C Applebaum
Two dosages of clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis.
The Pediatric infectious disease journal 2004;23(9):857-65.
2003: Frederick A Browne; Bülent Bozdogan; Catherine Clark; Linda M Kelly; Lois M Ednie; Klaudia Kosowska; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
Antimicrobial agents and chemotherapy 2003;47(12):3815-24.
2003: Bülent Bozdogan; Peter C Appelbaum; Lois M Ednie; Ioanna N Grivea; George A Syrogiannopoulos
Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(9):966-9.
2003: George A Syrogiannopoulos; Ioanna N Grivea; Lois M Ednie; Bülent Bozdogan; George D Katopodis; Nicholas G Beratis; Todd A Davies; Peter C Appelbaum
Antimicrobial susceptibility and macrolide resistance inducibility of Streptococcus pneumoniae carrying erm(A), erm(B), or mef(A).
Antimicrobial agents and chemotherapy 2003;47(8):2699-702.
2003: Dianne B Hoellman; Gengrong Lin; Lois M Ednie; Ashok Rattan; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.
Antimicrobial agents and chemotherapy 2003;47(3):1148-50.
2003: Lois M Ednie; Ashok Rattan; Michael R Jacobs; Peter C Appelbaum
Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.
Antimicrobial agents and chemotherapy 2003;47(3):1143-7.
2002: Roman S Kozlov; Tatiana M Bogdanovitch; Peter C Appelbaum; Lois M Ednie; Leonid S Stratchounski; Michael R Jacobs; Bülent Bozdogan
Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia.
Antimicrobial agents and chemotherapy 2002;46(9):2963-8.
2002: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
The Journal of antimicrobial chemotherapy 2002;50(1):101-5.
2002: Catherine L Clark; Kensuke Nagai; Bonifacio Dewasse; Glenn A Pankuch; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activity of cefditoren against respiratory pathogens.
The Journal of antimicrobial chemotherapy 2002;50(1):33-41.
2002: Dianne B Hoellman; Linda M Kelly; Kim Credito; Lauren Anthony; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
Antimicrobial agents and chemotherapy 2002;46(1):220-4.
2001: K Nagai; Todd A Davies; Lois M Ednie; André Bryskier; E Palavecino; Michael R Jacobs; Peter C Appelbaum
Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
Antimicrobial agents and chemotherapy 2001;45(11):3242-5.
2000: Todd A Davies; Lois M Ednie; D M Hoellman; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of ABT-773 compared to those of 10 other agents.
Antimicrobial agents and chemotherapy 2000;44(7):1894-9.
2000: Lois M Ednie; Kim Credito; M Khantipong; Michael R Jacobs; Peter C Appelbaum
Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
The Journal of antimicrobial chemotherapy 2000;45(5):633-8.
2000: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activity of gemifloxacin, a new broad-spectrum quinolone, against 200 pneumococci by four different susceptibility testing methods.
The Journal of antimicrobial chemotherapy 2000;45(4):525-8.
2000: Todd A Davies; Linda M Kelly; Dianne B Hoellman; Lois M Ednie; Catherine L Clark; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
Antimicrobial agents and chemotherapy 2000;44(3):633-9.
1999: Kim Credito; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
Antimicrobial agents and chemotherapy 1999;43(8):2027-31.
1998: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
Antimicrobial agents and chemotherapy 1998;42(9):2459-62.
1998: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
Antimicrobial agents and chemotherapy 1998;42(5):1269-73.
1998: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Anti-anaerobic activity of erythromycin, azithromycin and clarithromycin: effect of pH adjustment of media to compensate for pH shift caused by incubation in CO2.
The Journal of antimicrobial chemotherapy 1998;41(3):387-9.
1997: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).
Antimicrobial agents and chemotherapy 1997;41(9):2019-22.
1997: Lois M Ednie; SK Spangler; Michael R Jacobs; Peter C Appelbaum
Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.
Antimicrobial agents and chemotherapy 1997;41(5):1037-41.
1997: Lois M Ednie; SK Spangler; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.
Antimicrobial agents and chemotherapy 1997;41(5):1033-6.
1996: E Fasola; SK Spangler; Lois M Ednie; Michael R Jacobs; Saralee Bajaksouzian; Peter C Appelbaum
Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(11):2661-3.
1996: Lois M Ednie; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(8):1950-2.